Portal de Periódicos da CAPES

Conditional switching of VEGF provides new insights into adult neovascularization and pro-angiogenic therapy

2002; Springer Nature; Volume: 21; Issue: 8 Linguagem: Inglês

10.1093/emboj/21.8.1939

1460-2075

Yuval Dor, Valentin Djonov, Rinat Abramovitch, Ahuva Itin, Glenn I. Fishman, Peter Carmeliet, Gadi Goelman, Eli Keshet,

Congenital heart defects research

Article15 April 2002free access Conditional switching of VEGF provides new insights into adult neovascularization and pro-angiogenic therapy Yuval Dor Yuval Dor Department of Molecular Biology, Hebrew University–Hadassah Medical School, Jerusalem, 91120 Israel Search for more papers by this author Valentin Djonov Valentin Djonov Department of Anatomy, Berne University, Switzerland Search for more papers by this author Rinat Abramovitch Rinat Abramovitch MRI/MRS Laboratory, HBRC, Hadassah University Hospital, Jerusalem, 91120 Israel Search for more papers by this author Ahuva Itin Ahuva Itin Department of Molecular Biology, Hebrew University–Hadassah Medical School, Jerusalem, 91120 Israel Search for more papers by this author Glenn I. Fishman Glenn I. Fishman Section of Myocardial Biology, Department of Medicine, Mount Sinai School of Medicine, New York, NY, USA Search for more papers by this author Peter Carmeliet Peter Carmeliet The Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, KU Leuven, B-3000 Leuven, Belgium Search for more papers by this author Gadi Goelman Gadi Goelman Department of Anatomy, Berne University, Switzerland Search for more papers by this author Eli Keshet Corresponding Author Eli Keshet Department of Molecular Biology, Hebrew University–Hadassah Medical School, Jerusalem, 91120 Israel Search for more papers by this author Yuval Dor Yuval Dor Department of Molecular Biology, Hebrew University–Hadassah Medical School, Jerusalem, 91120 Israel Search for more papers by this author Valentin Djonov Valentin Djonov Department of Anatomy, Berne University, Switzerland Search for more papers by this author Rinat Abramovitch Rinat Abramovitch MRI/MRS Laboratory, HBRC, Hadassah University Hospital, Jerusalem, 91120 Israel Search for more papers by this author Ahuva Itin Ahuva Itin Department of Molecular Biology, Hebrew University–Hadassah Medical School, Jerusalem, 91120 Israel Search for more papers by this author Glenn I. Fishman Glenn I. Fishman Section of Myocardial Biology, Department of Medicine, Mount Sinai School of Medicine, New York, NY, USA Search for more papers by this author Peter Carmeliet Peter Carmeliet The Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, KU Leuven, B-3000 Leuven, Belgium Search for more papers by this author Gadi Goelman Gadi Goelman Department of Anatomy, Berne University, Switzerland Search for more papers by this author Eli Keshet Corresponding Author Eli Keshet Department of Molecular Biology, Hebrew University–Hadassah Medical School, Jerusalem, 91120 Israel Search for more papers by this author Author Information Yuval Dor1, Valentin Djonov2, Rinat Abramovitch3, Ahuva Itin1, Glenn I. Fishman4, Peter Carmeliet5, Gadi Goelman2 and Eli Keshet 1 1Department of Molecular Biology, Hebrew University–Hadassah Medical School, Jerusalem, 91120 Israel 2Department of Anatomy, Berne University, Switzerland 3MRI/MRS Laboratory, HBRC, Hadassah University Hospital, Jerusalem, 91120 Israel 4Section of Myocardial Biology, Department of Medicine, Mount Sinai School of Medicine, New York, NY, USA 5The Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, KU Leuven, B-3000 Leuven, Belgium *Corresponding author. E-mail: [email protected] The EMBO Journal (2002)21:1939-1947https://doi.org/10.1093/emboj/21.8.1939 PDFDownload PDF of article text and main figures. ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions Figures & Info To gain insight into neovascularization of adult organs and to uncover inherent obstacles in vascular endothelial growth factor (VEGF)-based therapeutic angiogenesis, a transgenic system for conditional switching of VEGF expression was devised. The system allows for a reversible induction of VEGF specifically in the heart muscle or liver at any selected schedule, thereby circumventing embryonic lethality due to developmental misexpression of VEGF. Using this system, we demonstrate a progressive, unlimited ramification of the existing vasculature. In the absence of spatial cues, however, abnormal vascular trees were produced, a consequence of chaotic connections with the existing network and formation of irregularly shaped sac-like vessels. VEGF also caused a massive and highly disruptive edema. Importantly, premature cessation of the VEGF stimulus led to regression of most acquired vessels, thus challenging the utility of therapeutic approaches relying on short stimulus duration. A critical transition point was defined beyond which remodeled new vessels persisted for months after withdrawing VEGF, conferring a long-term improvement in organ perfusion. This novel genetic system thus highlights remaining problems in the implementation of pro-angiogenic therapy. Introduction Extensive formation of blood vessels takes place in the developing embryo, guided by stereospecific developmental cues. In the adult, neovascularization is mostly confined to the female reproductive system but is also induced in response to perturbations in oxygen homeostasis, primarily following occlusion of major blood vessels. Ischemia-driven neovascularization mediated by vascular endothelial growth factor (VEGF) (Dor and Keshet, 1997), acting together with a vessel remodeling process termed arteriogenesis (van Royen et al., 2001), operates to improve the perfusion of ischemic tissues. In most clinical settings, however, these natural adaptive responses to a compromised perfusion are insufficient and unable to halt the progression of an ischemic disease in the myocardium or in peripheral vessels. The reasoning behind pro-angiogenic therapy for ischemic diseases is that exogenous administration of an angiogenic factor(s) might augment the natural collateralization process to an extent that the need for a more drastic (e.g. surgical) intervention will be circumvented. Indeed, encouraging pre-clinical studies have already prompted clinical trials of pro-angiogenic therapy (for recent reviews on pre-clinical studies and clinical trials see Hammond and McKirnan, 2000; Simons et al., 2000; Freedman and Isner, 2001). However, there are growing concerns that the large gaps that exist in our knowledge regarding the fundamentals and mechanisms of neovascularization of adult organs jeopardize favourable outcomes of these trials (Carmeliet, 2000; Helisch and Schaper, 2000; Lee et al., 2000; Blau and Banfi, 2001; Laham et al., 2001). Several factors regarding adult neovascularization need to be considered with therapeutic angiogenesis. First, most contemplated pro-angiogenic therapies rely on the administration of a single factor, whereas the natural process is multi-factorial. As an illustration, precluding signaling through each of the five endothelial cell-specific tyrosine kinase receptors (VEGF-R1, VEGF-R2, VEGF-R3, Tie1 and Tie2) results in an abortive vessel formation and embryonic lethality (Gale and Yancopoulos, 1999). Further more, additional factors and signaling systems are essential for engagement with periendothelial cells [e.g. the platelet-derived growth factor (PDGF) system; Lindahl et al., 1997] and others still are required for specifying an arterial or a venous fate (e.g. ephrin-B2/ephrin-B4; Adams and Klein, 2000). The premise that a singly administered factor is capable of inducing all other complementary activities essential for formation of a fully functional network needs to be substantiated and the quality of induced vessels carefully examined. Secondly, it remains to be determined how such a complex morphogenetic process is executed in the absence of guiding cues and under circumstances where neither the normal dosage nor the spatial or temporal controls of the initiating morphogen are maintained. Improper connectivity might perturb rather than improve the coronary circulation. Thirdly, it has to be determined whether short-term therapy will produce stable vessels that will persist after withdrawal of the inductive stimulus. This issue is of particular concern in light of earlier studies showing that premature withdrawal of VEGF may lead to regression of immature vessels in settings of developmental and tumor angiogenesis (Alon et al., 1995; Benjamin and Keshet, 1997). Addressing these fundamental issues in pre-clinical studies has been hampered by several problems. Depending on the methodology used for growth factor delivery, complications may include insufficient or variable levels of VEGF in the target organ, ‘off target’ effects, insufficient duration of the stimulus, an accompanying inflammatory response and an immunological reaction. Thus, it has been difficult to determine whether a particular shortcoming is due to any of these external factors or, alternatively, due to a fundamental problem inherent to a single factor-based therapeutic angiogenesis in the adult. We sought an experimental genetic system that would circumvent the above shortcomings and allow evaluation of the performance of a particular growth factor under optimal conditions. To this end, a genetic switch was designed in a transgenic mouse system that allowed for the reversible induction of high levels of VEGF, the factor most frequently considered for therapeutic angiogenesis, exclusively at the selected target organ and was able to maintain the stimulus for the desired duration. The resultant acquired vascular network was analyzed structurally by visualizing its three-dimensional architecture and network connectivity with the aid of corrosion casting, and functionally by monitoring dynamic changes in blood oxygenation and tissue edema using magnetic resonance imaging (MRI). The results reported below, while demonstrating the promise of a VEGF-based therapy, also uncover some inherent obstacles that need to be resolved first. Results A transgenic mouse system for conditional switching of VEGF expression in selected organs To evaluate the feasibility of a VEGF-based pro-angiogenic therapy, we designed an animal model system in which a source of VEGF can be specifically induced in the target organ, steadily maintained for the desired duration and subsequently switched off. Considering previous findings that a slight deviation from the normal dosage of VEGF results in embryonic lethality (Carmeliet et al., 1996; Ferrara et al., 1996; Miquerol et al., 2000), we resorted to a conditional transgenic system for VEGF induction. Transgenic mice expressing a tetracycline-regulated transactivator protein (tTA) exclusively in the myocardium or liver were employed as ‘driver lines’. Another transgenic line harboring a VEGF164-encoding transgene (driven by a tetracycline-responsive promoter) was used as the ‘responder line’. The respective ‘driver’ mouse was mated with the VEGF ‘responder’ animal, and pups that inherited both transgenes were selected (see scheme in Figure 1A). The onset of VEGF induction in these animals and the duration of expression were tightly controlled through the inclusion or omission of tetracycline from the drinking water (‘off’ and ‘on’ modes, respectively). Littermates that inherited only one of the two transgenes and were concomitantly subjected to the same repression/induction regime served as controls. Heart-specific induction was achieved using a driver line in which tTA expression is driven by a myosin heavy chain-α (MHCα) heart-specific promoter, previously shown to be expressed specifically by cardiomyocytes (Yu et al., 1996). Liver-specific induction was obtained by using a driver line in which tTA expression is driven by a CCAAT/enhancer binding protein β (C/EBPβ) promoter (also known as liver activator protein or PLAP), expressed primarily in hepatocytes (Kistner et al., 1996). If kept unrepressed, misexpression of VEGF in either organ led to multiple developmental defects and embryonic lethality (Dor et al., 2001; our unpublished results). Furthermore, if repression was relieved during the first 2–3 weeks after birth (when extensive growth in either organ is still ongoing), death also ensued. In contrast, in the presence of tetracycline, tTA+/VEGF+ animals were born with the expected frequency and if VEGF induction was delayed until later than 3 weeks after birth there was no lethality. Figure 1.A transgenic mouse system for conditional switching of VEGF expression in the adult heart or liver. (A) Scheme of the binary transgenic system based on a tetracycline-regulated trans-activator protein driven by either a heart- or liver-specific promoter (‘driver’ lines) and a transgene encoding VEGF164 (‘responder’ line) (see text for details). (B) A heart-specific VEGF switch. VEGF expression was induced by withdrawing tetracycline 1 week after birth and retrieving hearts for analysis 3 weeks later. Upper panels show in situ hybridization with a VEGF probe using myocardial thin sections obtained from littermates control and double transgenic animals that have been processed and hybridized on the same slide. Note induced expression of VEGF in cardiomyocytes. Myocardial hypercellularity observed in the double transgenic heart is due to VEGF-mediated proliferation/recruitment of endothelial cell precursors. Bars, 50 μm. Bottom left: a low magnification view of heart sections hybridized with VEGF as above but autoradiographed through a direct contact with an X-ray film to highlight the overall distribution of VEGF-producing cells. Bottom right: Relative levels of VEGF expression in myocardial sections quantified by autogradiographic grains counts (average ± SD of three high-power fields from each of three independent hybridizations). (C) A liver-specific VEGF switch. VEGF expression was induced by withdrawing tetracycline 1 week after birth and retrieving livers for analysis 4 weeks later. Upper panels show in situ hybridization with a VEGF probe using hepatic thin sections obtained from littermates control and double transgenic animals that have been processed and hybridized on the same slide. Note induced expression of VEGF in hepatocytes. Bars, 50 μm. Bottom left: northern blot analysis of total liver RNA extracted from control animals and from double transgenic animal prior to tetracycline withdrawal (off), 1 month after an ‘on’ switch (on) and 1 month after an ‘on’ switch followed by 3 months in the presence of tetracycline (on>off). Bottom right: Relative levels of VEGF expression were determined by densitometric tracing of the autoradiogram distinguishing the endogenous from transgenic VEGF. Download figure Download PowerPoint In tTA+/VEGF+ animals VEGF164 expression was strongly induced upon withdrawal of tetracycline. In situ hybridization confirmed that when driven by MHCα-tTA, expression of VEGF was induced in most, if not all, cardiomyocytes (Figure 1B) and when driven by PLAP-tTA, in most, if not all, hepatocytes (Figure 1C). This was assurance that extensive areas within the respective organ would be affected by the secreted factor. Quantitatively, the level of VEGF expression in the myocardium was increased by ∼7-fold overall (Figure 1B) and the level of VEGF in the liver was increased by ∼11-fold compared with the level of endogenous VEGF (Figure 1C). The continuous production of VEGF in the liver also resulted in its accumulation in the serum to levels that are 5- to 10-fold higher than the normal level of 300 pg/ml, as determined by a VEGF enzyme-linked immunosorbent assay (ELISA). In contrast, we could not detect a significant elevation of VEGF in the serum with cardiac-specific overexpression. Further evidence that the system is tightly controlled and fully reversible is provided by the northern blot of a representative ‘liver switch’ experiment shown in Figure 1C. The transgenic VEGF allele is completely silent prior to the switch and is effectively re-repressed upon re-administration of tetracycline. VEGF induces unlimited formation of new blood vessels in the adult myocardium and liver To determine whether VEGF can promote the formation of new blood vessel in adult tissues when acting alone, VEGF expression was switched ‘on’ in the myocardium or liver of adult animals. Organs were retrieved at different times following a continuous exposure to the VEGF stimulus and their vasculature was analyzed. Shortly after inducing VEGF in the heart, there was a massive accumulation of cells interspersed in between the muscle fibres. These cells were tentatively assigned as endothelial precursor cells (EPCs) on the basis of expressing a panel of endothelial cell-specific markers (the characterization of EPCs and their possible origins will be described elsewhere; Y.Dor and E.Keshet, in preparation). Coalescence of these cells into discrete blood-filled vessels was subsequently apparent. Notably, new vessels continued to be formed as long as the VEGF stimulus was present. The continuous nature of the process was also apparent from experiments using short (3 h) BrdU pulses to tag endothelial cells in S phase, demonstrating a significant fraction of cycling endothelial cells at any time point during a 1–2 month course of VEGF induction (data not shown). Prolonged VEGF stimulus in the myocardium resulted in a very high vessel density and in formation of vessels with abnormally large lumens occupying a large fraction of the organ (Figure 2A). Thus, VEGF-promoted neovascularization in the adult myocardium does not appear to be a self-limiting process and is also not restricted by the exhaustion of some needed downstream factors. Figure 2.VEGF induces extensive vessel formation in the adult myocardium and liver. (A) Hematoxylin–eosin staining of myocardial sections following a 19-day myocardial VEGF switch. An exaggerated angiogenic response has produced many vessels inter-digitizing muscle fibres and perturbing their normal architecture. Arrows point to the endothelium of these vessels. Bar, 100 μm. (B) A low-power view of the myocardium following a myocardial VEGF switch. Immunostaining with αSMA highlights large coronary vessels covered by VSMCs and pericytes. Note the higher abundance of αSMA-positive vessels in the VEGF-induced myocardium compared with control (quantified as a 2.4-fold increase through counting αSMA-positive vessels in the entire ventricular wall in five sections each). Bar, 1 mm. (C) Right: a higher magnification of the area boxed in (B). Note the presence of both VSMC-coated vessels (arrow) as well as uncoated vessels (arrowheads). Left: immunostaining with an endothelial cell-specific lectin (Bandeiraea simplicifolia BS-1 isolectin) performed on a serial section. Staining appearing in single cells presumably represent sections through capillaries as well as endothelial precursor cells. Bars, 100 μm. (D) Whole-mount views of a liver following a 30-day switch (a bottom view at the edge of the lobes). Note the elaborate vascular tree induced by VEGF. Bar, 1 mm. Download figure Download PowerPoint To determine whether VEGF can promote formation of large coronary vessels coated with vascular smooth muscle cells (VSMCs), myocardial sections were immunostained with the SMC/pericyte-specific marker α-smooth muscle actin (αSMA). As shown in Figure 2B (low magnification) and in Figure 2C (high magnification), VEGF indeed promoted formation of large coronary vessels, a fraction of which are coated with smooth muscle cells. This result indicates that VEGF not only promotes formation of an endothelial plexus but also supports the recruitment of periendothelial cells, presumably by inducing other activities required to accomplish this function. This finding provides further support for the concept of a single factor-based pro-angiogenic therapy. As is evident from Figure 2C, VEGF also caused extensive edema, completely disrupting the otherwise tight muscle architecture. Parallel experiments using a liver-specific VEGF switch demonstrated that VEGF also induced robust liver neovascularization. The elaborate vascular network induced by VEGF is clearly visible by external inspection (Figure 2D). Notably, the induced network is properly connected to the hepatic circulation, as evidenced by the fact that it carries blood. Histological examination has shown that vessels induced by VEGF in the liver are mostly large sinusoidal vessels (Figure 5A). Figure 3.Corrosion casts of epicardial vessels. Corrosion casts were prepared and scanned as described in Materials and methods. Data shown are of 10-week-old littermates. (A) Control heart. (B) Four weeks after switching ‘on’ VEGF. Arrows point at examples where flattened vessels merge with hemangioblastoma-like vessels. Arrowhead points at an abnormal multiple branching patterns. (C) Four weeks of ‘on’ followed by 8 days of ‘off’. Bars represent 50 μm in (A) and (C), and 100 μm in (B). Download figure Download PowerPoint Abnormal structure and connectivity of an induced myocardial network For optimal functioning, new vessels induced by VEGF must not only form a well-graded vascular tree but also appropriately connect with the existing coronary network. To visualize the three-dimensional architecture of the induced coronary network, corrosion casts were prepared and inspected by scanning electron microscopy. This methodology visualizes the entire vascular tree at a resolution that includes even the smallest capillaries. Since it detects only perfused vessels accessible to the casting resin, it highlights only functional vascular loops connected to the systemic circulation. A typical segment of the myocardial vascular tree in control heart is shown in Figure 3A. Switching ‘on’ VEGF expression and maintaining the stimulus for several weeks led to progressive ramification of the vasculature. Initially, this was evident mostly by reduced inter-capillary distance, and by structures suggestive of ongoing fusion events between contacting small vessels (see Supplementary figure 1 available at The EMBO JournalOnline). Further progression of the process during later stages resulted in the generation of very large vessels and eventually in the production of hemangioma-like vascular sacs (see Figure 3B for a representative example). Some of the vessels shown in Figure 3B seem to be in the process of flattening on top and merging their lumens with those of existing larger vessels (arrows). Abnormal structural features of these vessels included a variable diameter in consecutive segments within a single vessel, a large proportion of vessels with multiple rather than bimodal branching points (arrowhead) and abnormal branching angularities (Figure 3B). Thus, it appears that in the absence of guiding cues, vessels induced by VEGF in the adult myocardium connect with the existing coronary network in a highly chaotic manner. Interestingly, following VEGF withdrawal, the network resumed a more ‘normal’ appearance (Figure 3C; discussed below). Figure 4.MRI analysis of vascular function and permeability. Left and middle panels: MRI images of the liver. Images shown for a double transgenic animal were derived from the same coronal or axial section taken prior to (tg off) or at the indicated time after switching ‘on’ VEGF. d, days. Note progressive whitening of the image indicative of increased water retention (i.e. edema). Also note the formation of very large vessels discernible even at this low resolution. Right panels: vascular function (VF) in the same axial section shown in the middle panels was determined as described in Materials and methods. A progressive increase in the level of oxygenation is evident, represented on a color-coded relative scale. Download figure Download PowerPoint Vessels induced by VEGF improve organ perfusion but are leaky: an MRI analysis To determine whether the vascular gain resulting from a sustained VEGF stimulus improves liver perfusion, we monitored the ability of the organ to respond to dynamic changes in the level of inspired oxygen using non-invasive MRI. Briefly, at different time points after the onset of a VEGF switch animals were anesthetized and imaged during inhalation of air and subsequently during inhalation of an oxygen-enriched (95%) atmosphere. Changes in hemoglobin saturation were then detected by T2*-weighted gradient echo imaging using the intrinsic contrast generated by changes in deoxyhemoglobin content. An increased MRI signal reflects an improved capacity of erythrocytes to deliver inhaled oxygen to the tissue that, in this experimental setting, is due to increased vascularization and thus an improved perfusion (Abramovitch et al., 1998; Carmeliet et al., 1998). A recent study further validated the utility of blood oxygenation level detection (BOLD) contrast MRI for spatial mapping of vascular function through direct comparison with spectroscopic data obtained using intravital microscopy (Neeman et al., 2001). As shown in Figure 4 (right hand panels) from a representative animal, ongoing VEGF expression resulted in a progressive increase in the perfusion capability of the liver. A significant increase was already detected 11 days after the induction of VEGF and was further improved by day 20, reaching a remarkable 4-fold increase overall (for quantification see Figure 6A). As is evident from Figure 4, perfusion was improved in vast areas distributed throughout the liver. These findings demonstrate that new vessels induced by VEGF in an adult organ can indeed improve vascular function. At this time, this analysis has not been extended to the heart because taking MRI recordings from a fast beating organ requires instrumentation that is not currently available to us. Figure 5.Vascular phenotypes resulting from switching off VEGF. (A) Hematoxylin–eosin-stained sections of liver specimens obtained from littermate control (left), tTA+/VEGF+ animals 14 days after switching on VEGF (middle) and from tTA+/VEGF+ animals 14 days after switching on VEGF followed by switching off for 10 days (right). (B) Whole-mount views of livers. tTA+/VEGF+ livers before (left) and after (middle) the indicated times of an ‘on’ switch, and after an additional 5 weeks of an ‘off’ switch (right). Bar, 1 mm. (C) Top view of the entire liver from a control (left) and 4 months after switching off VEGF (following a 4 week stimulus). Download figure Download PowerPoint Figure 6.Long-term improvement of vascular function in the absence of edema. Monitoring vascular function (A) and edema (B) using MRI was performed as described in the legend to Figure 4. VEGF production was induced in tTA+/VEGF+ animal on day 0 and was switched off either at day 13 (arrow) or at day 32 (arrowhead). Each animal was imaged at the indicated times (squares, short switch; triangles, long switch) and each experimental point represents the average ± SD of readings from four animals. The pre-induction reading in (A) was used as a reference for determining relative increase in liver oxygenation. For monitoring liver edema in (B), the signal intensity in the liver was standardized in each section for the signal intensity in an irrelevant tissue (muscle) whose water content was not affected by VEGF produced by the liver. Download figure Download PowerPoint MRI analysis was also useful for online monitoring of edema resulting from VEGF overexpression, as was evident from the ‘whitening’ of the liver due to an elevated water retention (Figure 4, left hand panels). Excessive vessel permeability and a resultant edema were evident from early on and were further aggravated by a sustained VEGF stimulus (Figures 4 and 6B). A considerable enlargement (up to 3-fold) of the edematous liver was also evident from the MRI images. This finding underscores another major problem inherent to a VEGF-based therapy, namely the need to uncouple these two activities of VEGF/vascular permeability factor (VPF). A critical duration of the VEGF stimulus is essential for preventing vessel regression and for long-term persistence of the vascular gain To determine whether vessels induced in an adult organ are unstable and require a continuing presence of VEGF, we took advantage of the reversibility of the tetracycline-regulated transgenic system. VEGF expression in the liver was induced and maintained for 2 weeks. Under these conditions, an elaborate network was produced that is clearly visible in sections as a network of sinusoidal vessels, giving the liver a distinct ‘spongy’ appearance (Figure 5A). Mice were then given tetracycline and sections were inspected 10 days later. As shown in Figure 5A, most acquired vessels have disappeared and the normal ‘tight’ appearance of the liver was restored. The regression of vessels as the result of VEGF withdrawal was also apparent from external inspection of superficial hepatic vessels that have almost completely disappeared where VEGF was withdrawn 2 weeks after the onset of the switch (Figure 5B). In a marked contrast, delaying the ‘off’ switch until 4 weeks after its onset have shown that vessels have become refractory to VEGF withdrawal (Figure 5B). Remarkably, under these circumstances the acquired vasculature persisted for many months after cessation of the VEGF stimulus (Figure 5C; for several examples of acquired hepatic vessels persisting 8 months after VEGF withdrawal, see Supplementary figure 2). These findings indicate that there is a critical transition point beyond which the initially unstable vessels no longer need VEGF for survival. Similar experiments of VEGF withdrawal were also carried out in the heart. In particular, we wished to determine the nature of the vascular network that might persist after terminating the VEGF stimulus. To this end, the system was switched off after 4 weeks of a contin